The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma
Authors:
- Yuki SatoYSYuki Sato
- Daichi FujimotoDFDaichi Fujimoto
- Keiichiro UeharaKUKeiichiro Uehara
- Ryoko ShimizuRSRyoko Shimizu
- Jiro ItoJIJiro Ito
- Mariko KogoMKMariko Kogo
- Shunsuke TeraokaSTShunsuke Teraoka
- Ryoji KatoRKRyoji Kato
- Kazuma NagataKNKazuma Nagata
- Atsushi NakagawaANAtsushi Nakagawa
- Kojiro OtsukaKOKojiro Otsuka
- Hiroshi HamakawaHHHiroshi Hamakawa
Open Access
- 14 November 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Abstract
This study aimed to assess the prognostic accuracy of serum CA 19-9 in patients with advanced lung adenocarcinoma. We retrospectively reviewed data of 246 patients who were diagnosed at our institute with advanced (stage IIIB or IV) lung adenocarcinoma between March 2006 and December 2012. We excluded patients who received no chemotherapy, or for whom we had no data on pre-treatment tumor markers. We also evaluated 116 consecutive resected specimens from patients with clinical stage I lung adenocarcinoma pathologically. The 76 (31 %) patients who were CA 19-9+ had shorter overall survival (OS) than CA 19-9− group (12.5 vs 26.2 months, P = 0.005). Cox’s multivariate regression analysis identified Eastern Cooperative Oncology Group Performance Status 0 or 1 (P < 0.001), mutated epidermal growth factor receptor (EGFR) status (P < 0.001), stage IIIB (P < 0.001), CYFRA 21-1− (P < 0.001), CA 19-9− (P = 0.005) and use of platinum doublet therapy (P = 0.034) as independent predictors of longer OS. We stratified patients by CA 19-9 and CYFRA 21-1 as double positive (CA 19-9+/CYFRA 21-1+, n = 59), single positive (either CA19-9+ or CYFRA 21-1+, n = 113), or double negative (CA 19-9−/CYFRA 21-1−, n = 74). Their respective OS were 10.0, 23.3 and 31.8 months (P < 0.001). Pathological analysis also correlated CA 19-9 expression with malignant features such as vessel invasion, pleural invasion, cancer invasive factors and mucin production. CA 19-9 and CYFRA 21-1 are independent prognostic markers in patients with advanced lung adenocarcinoma. Combined use of CA 19-9 and CYFRA 21-1 provides further prognostic information in patients with advanced lung adenocarcinoma.Keywords
This publication has 35 references indexed in Scilit:
- Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective studyBMC Cancer, 2013
- Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line TherapyFrontiers in Oncology, 2013
- Significance of Serum Concentrations of E-selectin and CA19-9 in the Prognosis of Colorectal CancerJapanese Journal of Clinical Oncology, 2010
- CA19‐9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapyAsia-Pacific Journal of Clinical Oncology, 2010
- Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation AnalysisJournal of Thoracic Oncology, 2010
- Serum Levels of CA19‐9 in patients with nonmalignant respiratory diseasesJournal of Clinical Laboratory Analysis, 2007
- Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinomaJournal of Surgical Oncology, 2006
- Treatment of Bronchorrhea by Corticosteroids in a Case of Bronchioloalveolar Carcinoma Producing CA19-9.Internal Medicine, 2002
- ABH and Lewis histo‐blood group antigens in cancerAPMIS, 2001
- Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 1993